Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | GMNN | O75496 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ether SCHEMBL6495162 | 0.91 | LMNA (0.36) | LMNASMN1; SMN2SLC22A6ALOX15FFAR3 | |
| SCHEMBL2232097 | 0.88 | CYP1A2 (0.39) | LMNASMN1; SMN2CYP1A2MAPK1MEN1 | |
| SCHEMBL28068435 | 0.82 | MMP12 (0.43) | LMNASMN1; SMN2SLC22A6FFAR3CYP1A2 | |
| SCHEMBL25517 | 0.82 | — | — | |
| SCHEMBL25825 | 0.80 | LMNA (0.38) | LMNASMN1; SMN2SLC22A6FFAR3CYP1A2 | |
| SCHEMBL5672245 | 0.80 | — | — | |
| SCHEMBL3030610 | 0.80 | CHRM1 (0.42) | LMNASMN1; SMN2SLC22A6ALOX15CYP1A2 | |
| Ammonia Solution, Strong SCHEMBL22607979 | 0.80 | MMP12 (0.42) | LMNASMN1; SMN2SLC22A6FFAR3CYP1A2 | |
| SCHEMBL4458105 | 0.80 | LMNA (0.33) | LMNASMN1; SMN2CYP1A2MAPK1MEN1 | |
| SCHEMBL10414980 | 0.78 | LMNA (0.60) | LMNASMN1; SMN2ALOX15CYP1A2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256209-A1 | COMPOSITIONS COMPRISING ETHER COMPOUNDS AND PHARMACEUTICAL USES THEREFOR | ESPERION THERAPEUTICS, INC. | 2010-10-07 | — | — | US | disclosed |
| US-7709515-B2 | Compositions comprising ether compounds and pharmaceutical uses therefor | ESPERION THERAPEUTICS, INC. (US) | 2010-05-04 | — | — | US | disclosed |
| EP-1204626-B1 | ETHER COMPOUNDS, COMPOSITIONS, AND USES THEREOF | ESPERION THERAPEUTICS INC (US) | 2008-01-16 | — | — | EP | disclosed |
| EP-1862444-A2 | Ether compounds, compositions, and uses thereof | Esperion Therapeutics, Inc. (US) | 2007-12-05 | — | — | EP | disclosed |
| EP-1849760-A1 | Ether compounds, compositions, and uses thereof | Esperion Therapeutics Inc. (US) | 2007-10-31 | — | — | EP | disclosed |
| US-7192940-B2 | Ether compounds | ESPERION THERAPEUTICS, INC. (US) | 2007-03-20 | — | — | US | disclosed |
| US-20050119333-A1 | Compositions comprising ether compounds and pharmaceutical uses therefor | ESPERION THERAPEUTICS, INC. | 2005-06-02 | — | — | US | disclosed |
| US-20050004082-A1 | Therapy for cardiovascular, metabolism and cholesterol disorders | ESPERION THERAPEUTICS, INC. | 2005-01-06 | — | — | US | disclosed |
| US-6831105-B2 | For therapy and prophylaxis of cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders | ESPERION THERAPEUTICS, INC. | 2004-12-14 | — | — | US | disclosed |
| US-6790953-B2 | CARDIOVASCULAR DISORDERS, ANTIDIABETIC AGENTS, ALZHEIMER'S DISEASES, ANTIINFLAMMATOY AGENTS, ANTICANCER AGENTS | ESPERION THERAPEUTICS, INC. | 2004-09-14 | — | — | US | disclosed |
| US-6646170-B2 | Hydroxy derivatives; cardiovascular diseases, dyslipidemias, dysproteinemias, glucose metabolism disorders | ESPERION THERAPEUTICS, INC. | 2003-11-11 | — | — | US | disclosed |
| US-20030149094-A1 | Compositions comprising ether compounds and pharmaceutical uses therefor | ESPERION THERAPEUTICS, INC. | 2003-08-07 | — | — | US | disclosed |
| US-20030125559-A1 | Methods for synthesizing ether compounds and intermediates therefor | ESPERION THERAPEUTICS, INC. | 2003-07-03 | — | — | US | disclosed |
| EP-1204626-A4 | ETHER COMPOUNDS, COMPOSITIONS, AND USES THEREOF | ESPERION THERAPEUTICS INC (US) | 2003-05-07 | — | — | EP | disclosed |
| US-20030065195-A1 | Ether compounds | ESPERION THERAPEUTICS, INC. | 2003-04-03 | — | — | US | disclosed |
| US-6506799-B1 | Treating or preventing a cardiovascular disease in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically effective amount of 6-(6-hydroxy-5,5-dimethylhexyloxy)-2,2-dimethyl-hexan-1-ol and | ESPERION THERAPEUTICS, INC. | 2003-01-14 | — | — | US | disclosed |
| US-6459003-B1 | ETHER COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS, METABOLISM DISORDERS AND CHOLESTEROL DISORDERS | ESPERION THERAPEUTICS, INC. | 2002-10-01 | — | — | US | disclosed |
| US-6410802-B1 | ETHERIFICATION IN PRESENCE OF BASE | ESPERION THERAPEUTICS, INC. | 2002-06-25 | — | — | US | disclosed |
| EP-1204626-A1 | ETHER COMPOUNDS, COMPOSITIONS, AND USES THEREOF | Esperion Therapeutics Inc. (US) | 2002-05-15 | — | — | EP | disclosed |
| WO-2000059855-A1 | ETHER COMPOUNDS, COMPOSITIONS, AND USES THEREOF | ESPERION THERAPEUTICS, INC. (US) | 2000-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256209-A1 | COMPOSITIONS COMPRISING ETHER COMPOUNDS AND PHARMACEUTICAL USES THEREFOR | GPR119, ECHS1, PNLIP | LMNA 2702/4885SMN1; SMN2 2995/4885SLC22A6 2617/4885 |
| US-20030125559-A1 | Methods for synthesizing ether compounds and intermediates therefor | ECHS1, GPR119, PC | LMNA 2210/4885SMN1; SMN2 2784/4885SLC22A6 3201/4885 |
| US-20030065195-A1 | Ether compounds | GPR119, PPARG, PNLIP | LMNA 2498/4885SMN1; SMN2 2175/4885SLC22A6 3116/4885 |
| US-20050004082-A1 | Therapy for cardiovascular, metabolism and cholesterol disorders | GPR119, NR1H2, PC | LMNA 2683/4885SMN1; SMN2 2218/4885SLC22A6 2600/4885 |
| US-20030149094-A1 | Compositions comprising ether compounds and pharmaceutical uses therefor | GPR119, ECHS1, PNLIP | LMNA 2702/4885SMN1; SMN2 2995/4885SLC22A6 2617/4885 |
| US-20050119333-A1 | Compositions comprising ether compounds and pharmaceutical uses therefor | GPR119, ECHS1, PNLIP | LMNA 2702/4885SMN1; SMN2 2995/4885SLC22A6 2617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.